Results 101 to 110 of about 6,789 (241)

Prognostic Significance of Bile Duct Loss in Early‐Stage Primary Biliary Cholangitis: A Long‐Term Observational Study

open access: yesHepatology Research, Volume 55, Issue 12, Page 1621-1630, December 2025.
Bile duct loss on liver biopsy predicts future liver‐related events in early‐stage primary biliary cholangitis, even in patients with preserved liver function. This finding highlights the prognostic value of histological bile duct assessment at diagnosis and may guide early risk stratification and management decisions.
Taiki Okumura   +15 more
wiley   +1 more source

Primary Biliary Cholangitis With Incomplete Response to Conventional Therapies But Had Complete Response to Baricitinib: A Case Report

open access: yesCase Reports in Hepatology
Primary biliary cholangitis is a progressive disease with complications such as liver cirrhosis and hepatocellular carcinoma, and the treatment goal is to delay its progression.
Gi Eun Kim   +3 more
doaj   +1 more source

Molecular Mechanisms of Nonalcoholic Fatty Liver Disease: Potential Role for 12-Lipoxygenase [PDF]

open access: yes, 2017
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of pathologies associated with fat accumulation in the liver. NAFLD is the most common cause of liver disease in the United States, affecting up to a third of the general population.
Anderson, Ryan M.   +4 more
core   +1 more source

Ganoderic Acid A Alleviates High‐Fat Diet‐Induced Lipid Metabolism Disorders in Mice by Inhibiting Intestinal Farnesoid X Receptor

open access: yesFood Frontiers, Volume 6, Issue 6, Page 3108-3121, November 2025.
Ganoderic acid A (GA) improved lipid metabolism disorders by inhibiting intestinal FXR. GA markedly suppressed the ileal intestinal FXR activity. Then, GA changed bile acid composition and upregulated hepatic Cyp7a1 mRNA through decreasing FXR target genes encoded protein levels.
Feng Lu   +7 more
wiley   +1 more source

Benzoxazole Derivatives as Potent FXR and PPARα Dual Agonists With Anti‐Fibrotic and Metabolic Regulatory Effects

open access: yesMedComm, Volume 6, Issue 11, November 2025.
MHY5396, a benzoxazole derivative, functions as a potent dual FXR and PPARα agonist. It exhibits significant anti‐fibrotic and metabolic regulatory effects, effectively improving liver and kidney fibrosis in experimental models. These findings highlight its potential as a therapeutic candidate for fibrosis and metabolic disorders.
Mi‐Jeong Kim   +15 more
wiley   +1 more source

Acute-on-chronic liver failure in cirrhosis [PDF]

open access: yes, 2016
The definition of acute-on-chronic liver failure (ACLF) remains contested. In Europe and North America, the term is generally applied according to the European Association for the Study of the Liver-Chronic Liver Failure (EASL-CLIF) Consortium guidelines,
Arroyo, V   +9 more
core  

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial [PDF]

open access: yes, 2019
Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH.
Abdelmalek, Manal   +370 more
core   +1 more source

Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult‐to‐treat primary biliary cholangitis

open access: green, 2021
Pierre‐Antoine Soret   +27 more
openalex   +2 more sources

Pregnane X receptor and constitutive androstane receptor modulate differently CYP3A-mediated metabolism in earlyand late-stage cholestasis [PDF]

open access: yes, 2017
AIM: To ascertain whether cholestasis affects the expression of two CYP3A isoforms (CYP3A1 and CYP3A2) and of pregnane X receptor (PXR) and constitutive androstane receptor (CAR).
Albertoni, Laura   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy